Lapacent 250 mg (Tablet)
Unit Price: ৳ 300.00 (2 x 6: ৳ 3,600.00)
Strip Price: ৳ 1,800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lapatinib |
| Company | Incepta pharmaceuticals ltd |
Indications
- Treatment of advanced or metastatic breast cancer
- Combination therapy for HER2-positive metastatic breast cancer
- Hormonal therapy for hormone receptor-positive metastatic breast cancer
- Limitations of use for patients who have disease progression on Trastuzumab
Pharmacology
- Kinase inhibitor of EGFR and HER2 receptors
- Inhibition of ErbB-driven tumor cell growth
- Additive effect in combination with 5-FU
- Inhibition of BCRP, P-gp, and OATP transporters
Dosage & Administration
- Oral administration
- 1,250 mg daily dose for HER2-positive metastatic breast cancer
- 1,500 mg daily dose in combination with Letrozole
- Dosing schedule in repeating 21-day cycles
- Dose adjustment for missed doses
- Safety and effectiveness in pediatric patients not established
Interaction
- Inhibition of CYP3A4, CYP2C8, and P-gp enzymes
- Significant interaction with drugs metabolized by CYP3A4
- Effects on Midazolam, Paclitaxel, and Digoxin metabolism
- Potentiation by Ketoconazole and inhibition by Carbamazepine
- Substrate of efflux transporter P-glycoprotein (P-gp)
Contraindications
- Severe hypersensitivity to Lapatinib or its components
Side Effects
- Common adverse reactions: diarrhea, nausea, rash, vomiting, fatigue
Pregnancy & Lactation
- Potential fetal harm
- Adverse effects on breastfed child
- Advice against breastfeeding during treatment
Precautions & Warnings
- Decreased Left Ventricular Ejection Fraction (LVEF)
- Hepatotoxicity and liver function monitoring
- Management and intervention for Lapatinib-induced diarrhea
- Monitoring for interstitial lung disease, QT prolongation, and severe cutaneous reactions
Use in Special Populations
- Dose modification guidelines for cardiac events, hepatic impairment, and diarrhea
- Interactions with CYP3A4 inhibitors and inducers
- Discontinuation or interruption of dosing for toxicity management
Overdose Effects
- No known antidote
- Max oral doses administered in clinical trials
- Symptoms and reported cases of overdose
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Store below 30°C in a dry place
- Keep out of the reach of children